These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22172384)

  • 21. Efficacy of nimotuzumab (hR3) conjugated with
    Nguyen TT; Ho AS; Nguyen TK; Nguyen TN; Bui VC; Nguyen TB; Dang HH; Nguyen DK; Nguyen TN; Nguyen LT
    Int J Radiat Biol; 2021; 97(5):704-713. PubMed ID: 33617414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab improves the delivery and efficacy of paclitaxel.
    Yanagisawa M; Yorozu K; Kurasawa M; Nakano K; Furugaki K; Yamashita Y; Mori K; Fujimoto-Ouchi K
    Anticancer Drugs; 2010 Aug; 21(7):687-94. PubMed ID: 20559127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
    DeNardo SJ; Kukis DL; Kroger LA; O'Donnell RT; Lamborn KR; Miers LA; DeNardo DG; Meares CF; DeNardo GL
    Proc Natl Acad Sci U S A; 1997 Apr; 94(8):4000-4. PubMed ID: 9108094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.
    Volk LD; Flister MJ; Chihade D; Desai N; Trieu V; Ran S
    Neoplasia; 2011 Apr; 13(4):327-38. PubMed ID: 21472137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay.
    Ingargiola M; Runge R; Heldt JM; Freudenberg R; Steinbach J; Cordes N; Baumann M; Kotzerke J; Brockhoff G; Kunz-Schughart LA
    Int J Cancer; 2014 Aug; 135(4):968-80. PubMed ID: 24615356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.
    Masters GR; Berger MA; Albone EF
    Gynecol Oncol; 2006 Sep; 102(3):462-7. PubMed ID: 16434088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
    Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
    J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
    Forero A; Meredith RF; Khazaeli MB; Shen S; Grizzle WE; Carey D; Busby E; LoBuglio AF; Robert F
    Cancer Biother Radiopharm; 2005 Oct; 20(5):467-78. PubMed ID: 16248762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.
    Cardillo TM; Ying Z; Gold DV
    Clin Cancer Res; 2001 Oct; 7(10):3186-92. PubMed ID: 11595713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
    Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
    O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
    Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.
    Zhang M; Yao Z; Garmestani K; Yu S; Goldman CK; Paik CH; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Cancer Biother Radiopharm; 2009 Jun; 24(3):303-9. PubMed ID: 19538052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
    Miers L; Lamborn K; Yuan A; Richman C; Natarajan A; DeNardo S; DeNardo G
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7158s-7163s. PubMed ID: 16203816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
    Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
    Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines.
    Supiot S; Gouard S; Charrier J; Apostolidis C; Chatal JF; Barbet J; Davodeau F; Cherel M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7047s-7052s. PubMed ID: 16203801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
    Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
    J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.